Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf(Research Institute of Molecular Pathology), Joan Massagué(Memorial Sloan Kettering Cancer Center), Roger S. Lo(University of California, Los Angeles), Yilong Zou(Westlake University), Neal Rosen(Memorial Sloan Kettering Cancer Center), Hubing Shi(Sichuan University), Marcus Bosenberg(Yale University), Sakari Vanharanta(University of Helsinki), Xiangju Kong(University of California, Los Angeles), Thomas Wiesner, Weiping Shu(Memorial Sloan Kettering Cancer Center), Andrew L. Ji(Memorial Sloan Kettering Cancer Center)
Cited by 502
Related Papers
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
Smad transcription factors
|Genes & Development|2005|2.4k
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
|Cell|1994|2.1k
Metastatic colonization by circulating tumour cells
|Nature|2016|2k